NGM Biopharmaceuticals, Inc. announced that Siobhan Nolan Mangini, who has served as the company's Chief Financial Officer (CFO) since July 2020, has been appointed to the additional role of President of NGM Bio. William J. Rieflin, who has served as Executive Chairman of NGM Bio's Board of Directors since September 2018, will transition to Chairman of the Board effective July 1, 2022. Prior to moving into his role as Executive Chairman, Mr. Rieflin served as NGM Bio's CEO and a member of the company's Board of Directors for eight years.

In addition to continuing to oversee business development, finance and accounting, and investor relations at NGM Bio, in her new role Ms. Nolan Mangini will oversee additional functions, including corporate and product strategy, information technology, and cybersecurity and real estate. Since joining NGM Bio, Ms. Nolan Mangini has supported the company in rapidly advancing its diverse portfolio through leading the company's revised collaboration with Merck in 2021 and raising over $170 million in equity proceeds to date, including spearheading NGM's public offering in 2021. Prior to joining NGM Bio, Ms. Nolan Mangini served as President and CFO of Castlight Health, a San Francisco-based healthcare technology company.

Before that, she worked as a management consultant at Bain & Company, specializing in the health care and private equity practices. Ms. Nolan Mangini has a Master of Business Administration from the Graduate School of Business at Stanford University, a Master of Public Administration from the Kennedy School of Government at Harvard University and a Bachelor of Science in Economics from the Wharton School at the University of Pennsylvania.